Anti-VEGF agents are broadly implicated in causing thrombotic microangiopathy (TMA) [13], kidney function impairment [14], or the onset or worsening of pre-existing hypertension and proteinuria [15, 16]. This evidence concerns the gene VEGFA and hypertensive disorder.